Concurrent glomerular PCDH7 deposits in PLA2R-associated membranous nephropathy.
Membranous nephropathy
Phospholipase A2 receptor
Podocytic antigen
Protocadherin 7
Renal pathology
Journal
CEN case reports
ISSN: 2192-4449
Titre abrégé: CEN Case Rep
Pays: Japan
ID NLM: 101636244
Informations de publication
Date de publication:
25 Dec 2023
25 Dec 2023
Historique:
received:
27
09
2023
accepted:
27
11
2023
medline:
25
12
2023
pubmed:
25
12
2023
entrez:
25
12
2023
Statut:
aheadofprint
Résumé
The understanding of membranous nephropathy (MN) has undergone impressive advancements in the last 5 years, particularly due to identification of novel antigenic targets. M-type phospholipase A2 receptor (PLA2R) and thrombospondin type 1 domain-containing 7A (THSD7A) account for approximately 70% and 1-5% of the target antigens in primary MN, respectively. Recently, more novel/putative antigens have been identified in the remaining cases of MN that include exostosin 1/exostosin 2 (EXT1/EXT2), neural epidermal growth factor-like 1 protein (NELL-1), semaphorin 3B (SEMA3B) and protocadherin 7 (PCDH7). However, comparatively little is known about the PCDH7 among these novel antigens. As such, we herein described a unique case of positive glomerular PCDH7 deposits in PLA2R-associated MN, which may offer a deeper insight into the role of PCDH7 in MN and improve our understanding of glomerular diseases in the post-COVID era, particularly with the emerging variants.
Identifiants
pubmed: 38145434
doi: 10.1007/s13730-023-00842-2
pii: 10.1007/s13730-023-00842-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Japanese Society of Nephrology.
Références
Sethi. New ‘antigens’ in membranous nephropathy. J Am Soc Nephrol. 2021;32:268–78.
doi: 10.1681/ASN.2020071082
pubmed: 33380523
Caravaca-Fontán F, Yandian F, Fervenza FC. Future landscape for the management of membranous nephropathy. Clin Kidney J. 2023;16:1228–38.
doi: 10.1093/ckj/sfad041
pubmed: 37529655
pmcid: 10387398
Morishita H, Yagi T. Protocadherin family: diversity, structure, and function. Curr Opin Cell Biol. 2007;19:584–92.
doi: 10.1016/j.ceb.2007.09.006
pubmed: 17936607
Sethi S, Madden B, Debiec H, et al. Protocadherin 7-associated membranous nephropathy. J Am Soc Nephrol. 2021;32:1249–61.
doi: 10.1681/ASN.2020081165
pubmed: 33833079
pmcid: 8259689
Zhou S, Meng FL, Yue SL, Li H, Zhang LH, Wang T. Backtracking cryptic recurrence of esophageal cancer from membranous nephropathy: the detection of glomerular NELL-1 and IgG4. Clin Kidney J. 2022;16:756–9.
doi: 10.1093/ckj/sfac261
pubmed: 37007702
pmcid: 10061426
Sethi S, Beck LH Jr, Glassock RJ, et al. Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification. Mayo Clin Proc. 2023;98:1671–84.
doi: 10.1016/j.mayocp.2023.08.006
pubmed: 37804268
Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014;371:2277–87.
doi: 10.1056/NEJMoa1409354
pubmed: 25394321
pmcid: 4278759
Sethi S, Madden B, Casal Moura M, et al. Hematopoietic stem cell transplant-membranous nephropathy is associated with protocadherin FAT1. J Am Soc Nephrol. 2022;33:1033–44.
doi: 10.1681/ASN.2021111488
pubmed: 35321939
pmcid: 9063902
Gee HY, Sadowski CE, Aggarwal PK, et al. FAT1 mutations cause a glomerulotubular nephropathy. Nat Commun. 2016;7:10822.
doi: 10.1038/ncomms10822
pubmed: 26905694
pmcid: 4770090
Huang G, Liu F, Yu L, Wang J, Chen J, Mao J. Pediatric membranous nephropathy: in the novel antigens era. Front Immunol. 2022;13: 962502.
doi: 10.3389/fimmu.2022.962502
pubmed: 36016931
pmcid: 9396344
Prema KSJ, Kurien A. Incidence of anti-glomerular basement membrane disease during the COVID-19 pandemic. Clin Kidney J. 2021;15:180–1.
doi: 10.1093/ckj/sfab204
pubmed: 35028133
pmcid: 8574335
Klomjit N, Zand L, Cornell LD, Alexander MP. COVID-19 and glomerular diseases. Kidney Int Rep. 2023;8:1137–50.
doi: 10.1016/j.ekir.2023.03.016
pubmed: 37274308
pmcid: 10041821
Mudd PA, Remy KE. Prolonged adaptive immune activation in COVID-19: implications for maintenance of long-term immunity? J Clin Investig. 2021;131: e143928.
doi: 10.1172/JCI143928
pubmed: 33104057
pmcid: 7773393
Yoshida S, Hanai S, Nakagomi D, Kobayashi K, Takahashi K, Furuya F. Membranous nephropathy with proteinase 3-ANCA-associated vasculitis successfully treated with rituximab. Intern Med. 2021;60:145–50.
doi: 10.2169/internalmedicine.4752-20
pubmed: 32830174
Feng J, Zhao W, Sun L, Zhang L, Li H, Wang T. A rare dual glomerulopathy with double antibodies against the podocytic phospholipase A2 receptor and glomerular basement membrane. Int Urol Nephrol. 2022;54:3295–7.
doi: 10.1007/s11255-022-03273-7
pubmed: 35725869
Zhao WT, Li J, Yang G, Ren GW, Zhang LH, Wang T. Non-typical anti-GBM disease with intraglomerular granulomatous reaction and anti-PLA2R-negative membranous nephropathy in the context of IgM/κ paraproteinemia. Int Urol Nephrol. 2023;55:1389–91.
doi: 10.1007/s11255-022-03424-w
pubmed: 36456884
Yamazaki T, Takahashi H, Takeuchi K, et al. Rare case of exostosin 1/exostosin 2-related membranous lupus nephritis concomitant with dual ANCA- and anti-GBM antibody-associated crescentic glomerulonephritis effectively diagnosed by mass spectrometry: a case report. BMC Nephrol. 2023;24:218.
doi: 10.1186/s12882-023-03268-1
pubmed: 37488532
pmcid: 10364369
Hoxha E, Reinhard L, Stahl RAK. Membranous nephropathy: new pathogenic mechanisms and their clinical implications. Nat Rev Nephrol. 2022;18:466–78.
doi: 10.1038/s41581-022-00564-1
pubmed: 35484394